Phase 1 Randomized, Double-Blind, Placebo-Controlled Study on Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Volunteers

The primary objective of this study is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of QRL-101 in healthy participants. This is a critical step in the drug development process, as it helps to ensure that the investigational product is safe for further testing in patient populations. Understanding the pharmacokinetics of QRL-101 will provide insights into how the drug is absorbed, distributed, metabolized, and excreted in the body, which is essential for determining appropriate dosing regimens. The study is designed as a randomized, placebo-controlled, double-blind, multiple ascending dose, phase 1 trial, which is a standard approach for initial human testing of new compounds.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range of the participants includes individuals from two categories, specifically 18-64 years and 65 years and older. The trial does not focus on a vulnerable population, and the selection criteria for participants have not been disclosed. The sponsor has not provided information regarding the total number of participants. Lifestyle considerations such as diet, physical activity, or habits have not been specified in the available data. The study does not target individuals with specific medical conditions, as it is designed for healthy volunteers.

The clinical trial is designed as a **randomized**, **placebo-controlled**, **double-blind**, multiple ascending dose, phase 1 study. The primary aim is to evaluate the safety, tolerability, and pharmacokinetics of QRL-101 in healthy participants. The trial is expected to commence recruitment on July 2, 2024, and conclude by December 2, 2024. Participants will be involved in the study for a duration that aligns with the trial's timeline, with specific involvement periods determined by the dosing schedule and follow-up requirements.

The trial will begin with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for inclusion. Following successful screening, participants will be randomly assigned to receive either the investigational product or a placebo in a blinded manner. The sequence of study visits will include regular follow-up assessments to monitor safety and collect pharmacokinetic data. These visits are crucial for evaluating the investigational product's effects and ensuring participant safety throughout the trial.

The end-of-study visit will mark the conclusion of a participant's involvement, during which final assessments will be conducted to gather comprehensive data on the investigational product's impact. Participants may be withdrawn from the study early if they experience adverse events that compromise their safety or if they fail to adhere to the study protocol. The trial's design ensures rigorous monitoring and data collection to achieve its objectives while maintaining participant safety and data integrity.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for any non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on July 2, 2024, with an estimated completion date of December 2, 2024. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the treatment's impact on the specified medical condition, utilizing appropriate clinical methodologies and tools as per standard Phase 3 trial protocols. The trial's design will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy outcomes.